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Vesicoureteral reﬂux (VUR) aﬀects approximately 1% of children and may predispose a child with a bladder infection to develop
pyelonephritis and renal scarring. To prevent these potential sequelae, one accepted treatment option for VUR includes low-
dose continuous antibiotic prophylaxis (CAP) to maintain urine sterility until the condition resolves. Despite the widespread use
of CAP, little data exists regarding adherence to long-term antibiotic therapy. Not only will poor adherence to CAP potentially
preclude the intended beneﬁt, but also nonadherence with antibiotic regimens may carry untoward eﬀects including unnecessary
treatment changes forpresumed antibiotic failure, emergence of resistantorganisms,andcompromisedclinicaltrial outcomes.We
present an overview of medication adherence in children with VUR, discuss possible consequences of nonadherence to antibiotic
prophylaxis, and suggest ways to improve adherence. We raise awareness of issues related to nonadherence relevant to healthcare
providers, investigators, and the community.
1.Introduction
Vesicoureteral reﬂux (VUR), a common congenital abnor-
mality, aﬀects approximately 1% of infants and children.
It may predispose a child with a bladder infection to the
developmentofpyelonephritis, which may lead to renal scar-
ring and hypertension [1]. To prevent these potential long-
term sequelae, one accepted treatment option for persistent
VUR includes low-dose continuous antibiotic prophylaxis
(CAP). Since reﬂux has a 5–13% annual spontaneous
resolution rate, CAP may be oﬀered as a protective measure
to maintain urine sterility until the condition resolves [2, 3].
Herein, the physician assumes the patient is taking the
antibiotic as prescribed on a daily basis.
Despite the widespread use of CAP, there is a paucity
of data regarding patient adherence to long-term antibiotic
therapy. The intended beneﬁt of any medication will be
completely achieved only if patients adhere to the pre-
scribed treatment regimen. Not only will nonadherence to
CAP potentially preclude the intended beneﬁt, but also
nonadherence with antibiotic regimens may carry potential
untoward eﬀects. For example, nonadhernence to antibiotics
isassociatedwiththeemergenceofresistant organisms [4,5].
In addition, recurrent UTIs in nonadherent patients with
VUR may be interpreted as treatment failure, and may
instigate unnecessary treatment changes. Nonadherence may
also compromise clinical trial outcomes and, consequently,
treatment guidelines derived from them.
The aim of this paper is to provide a brief overview of
medicationadherenceinchildrenwithVUR,discusspossible
consequencesofnonadherencetoantibiotic prophylaxis,and
suggest ways to improve adherence. Our goal is to raise
awareness of issues related to nonadherence relevant to
healthcare providers, investigators, and the community.
2.Adherence
The intended beneﬁt of any prescribed medication will be
fully achieved only if the patient adheres to the prescribed
treatment closely.Adherencetoa medicationregimen isgen-
erally deﬁned as the degree to which the medications taken
reﬂect the prescribing healthcare provider’s intention [6, 7].2 Advances in Urology
While there is no consensus on what constitutes adequate
adherence, an adherence rate of 80% or greater (antibiotic
c o v e r a g ef o r8 0 %o ft h ey e a ro rm o r e )i sc o m m o n l yu s e d
in the literature [8]. Similarly, there is no consensual gold
s t a n d a r dm e t h o df o rm e a s u r i n gw h e t h e rp a t i e n t st a k et h e
medication prescribed or not. Current methods used to
measure compliance are best categorized as direct and
indirect methods [8–10]. Direct methods include biologic
blood markers, level of medicine or metabolite in blood or
urine, and direct observation of ingestion. Indirect methods
include patient/caregiver questionnaire, medication diary,
medical record, pill counts, rates of prescription reﬁlls, and
patient’s clinical response. In general, direct methods more
reliably predict adherence; however, they are more costly and
time consuming. Many of the indirect methods are more
practical; however, they have been shown to overestimate
adherence [8–10]. Using a parent questionnaire, Smyth
showed that 97% of parents reported giving prophylactic
antibiotics every day; however, only 67% of urine samples
tested positive for antibacterial substance [11]. In a similar
study of children with VUR, in the group without recurrent
urine infections 84% of parents reported that their children
were taking antibiotics at 6 months but only 28% had a
positive urine antibiotic activity test; at 1 year 57% reported
their children were taking antibiotics but only 17% had
ap o s i t i v eu r i n et e s t[ 12]. It’s important to note that even
direct measuring methods with ultrasensitive blood or urine
tests may not be entirely reﬂective of adherence. Many
patients improve medication compliance just before seeing
their healthcare provider [13]. In this scenario, blood or
urinemedicationlevelonlyindicatesthatthemedicationwas
recently taken, but does not ascertain adherence in between
visits.
Regardless of the method used to measure adherence,
a common denominator among children with chronic
diseases such as asthma, diabetes, HIV, and skin diseases, is
thatpooradherence isa ubiquitousphenomenon. In a quan-
titative review of children with chronic diseases, DiMatteo
estimated that only about 70% of patients were adherent
to treatment recommendations [14]. However, other studies
have noted even lower rates, averaging about 50–60%, with
decreasing compliance rates noted over time [15–18]. In
a prospective study of children with asthma, adherence rates
toinhaledcorticosteroidsdecreasedfrom73%at4monthsto
59% at 12 months [19]. Even in clinical trials where patients
often receive more attention and, by nature, may self-select
for inherently motivated subjects, poor adherence rates are
notuncommon.In thePENTA5randomizedcontrolled trial
evaluating HIV treatment in children, 25% of subjects were
nonadherent with antiretroviral regimens [20].
Congruent with the poor adherence rates witnessed in
childrenwith otherchronicdiseases, adherencewith prophy-
lactic antibiotics in children with VUR is poor. Additionally,
with time, adherence with long-term antibiotic decreases
dramatically [10,12].Using large pharmacy claims databases
in children with VUR, two recent studies showed poor
prophylactic antibioticadherence asdeﬁned by an adherence
rateoflessthan80%.In theﬁrst study,Hensle and colleagues
reported a 17% adherence rate [21]. Similarly, in the second
study, Copp et al. reported a 40% adherence rate [22]. These
two recent reports substantiate previous ﬁndings where
antibiotic adherence rates at one year among children with
VURwereonly57%byparentalreportand17%bymeasured
urine levels of antibiotic activity [12].
3.PotentialConsequencesof Nonadherence
Omitting antibiotic doses may result in breakthrough UTIs,
which in addition to the discomfort and inconvenience
caused, may increase the risk for pyelonephritis and renal
scarring [1]. Furthermore, recurrent UTI’s in nonadher-
ent patients with VUR may be interpreted as treatment
failure, and may instigate unnecessary medication changes
or additional interventions such as imaging studies and/or
surgical correction of the underlying condition. Unnecessary
tests and treatments, hospital admissions, and additional
healthcare provider visits increase healthcare costs [23, 24].
Moreover, indirect costs and eﬀects such as workdays missed
by parents and school absences by children create a burden
that is diﬃcult to quantify.
In addition to aﬀecting the individual patient, poor
adherence may also have local and global ramiﬁcations.
Bacterial drug resistance is a growing problem and has
become a major public health concern. For example, EC o l i ,
which causes 70–90% of ﬁrst febrile uncomplicated UTIs
in children [25–28], is resistant to sulfonamides in up to
27% of cases in certain regions of the United States [29].
The emergence of drug resistant strains is more likely to
occur in nonadherent patients, as subtherapeutic antibiotic
levelshave been shown to foster the developmentof resistant
organisms [4, 5, 30].
Lastly, poor adherence may compromise clinical trial
outcomes and, consequently, treatment recommendations
derived from them. Four well-referenced contemporary ran-
domized controlled studies in children with VUR question
the beneﬁt of antibiotic prophylaxis as UTI, pyelonephritis,
and renal scaring were not statistically diﬀerent among
patients receiving versus not receiving CAP [30–33]. All
four studies failed to account for adherence to the antibiotic
treatment therapy. Since nonadherence has also been shown
to be an important factor in the research setting [20],
a possible explanation for these ﬁndings could simply be
due to a lack of adherence to the daily antibiotic prophylaxis
regimen.
As investigators we cannot assume that children/parents
are adherent to treatment. We must adequately account
for and report adherence rates in our studies. Adherence
estimates determined solely by the attending doctor should
be discouraged as they have been shown to be inaccurate
and overestimate true rates [34, 35]. In a prospective
study measuring compliance with antibiotic prophylaxis in
childrenwithsicklecellanemia,adherenceratewaslowwhen
measured byurinetests(56%)andparentalinterview (48%),
but overestimated by analysis of medical records (89%) [34].
Given its complexity, to maximize accuracy, a combination
of methods for measuring adherence is advocated. In this
manner we canmoreconﬁdentlybegintointerpretourstudy
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4.Improving Adherence
Given the potential individual and global ramiﬁcations of
noncompliance, interventions to promote compliance are
needed. This is particularly important in the pediatric popu-
lation where adherence to treatment regimens can be further
inﬂuenced by involvement of family members, develop-
mental capacity of the patient, and by unique psychosocial
issues implicit at a given age [36–40]. Hence, a multi-
faceted approach tailored to the individual child/parent
is needed to improve adherence [41–43]. Support from
ancillary health care providers such as nurses, behavioral
specialists, and pharmacists may increase adherence and
should be used as needed when feasible [44–46]. We
discuss approaches to enhance adherence for three age
groups: infant/toddler/preschool (0–<5yrs), young child (5–
<11yrs), and adolescent (11–<19yrs).
In infants/toddlers/preschoolers, the caregiver is pri-
marily responsible for the administration of the antibiotic.
Enhancing patient/parent-doctor communication has a piv-
otalrolein improving medication compliance[37, 47]. Here,
the health care provider should assure that the caregiver has
a solid understanding of the disease process, the beneﬁts
of the treatment regimen, and the risks of noncompliance.
Dosing and timing of the medication prescribed should be
discussed. As forgetfulness can be the main reason cited by
caregivers for omitting antibiotic doses [48], short interval
follow-up visits should be scheduled. This gives the health-
care provider an excellent opportunity to assess adherence
in a nonjudgmental way, and reiterate the importance of
following the treatment outlined. Also, the medication dose
can be adjusted, as infants grow rapidly during this age.
Although there is a paucity of literature describing the
most eﬀective ways of improving adherence in young chil-
dren,in generalacombinationofbehavioral andeducational
strategies are most beneﬁcial [49]. Education is typically tar-
geted at the caregiver responsible for administering the med-
ication, and involves written or verbal information about
the child’s illness, delineating reasons for treatment, and
discussing potential consequences of poor adherence [49].
Other forms of education include informational videotapes,
structured educational home visits by nurses or counselors,
and group discussions [49–56]. When feasible, similar age
appropriate verbal, written, and visual educational materials
should be provided to the child. There is a wide spectrum
of behavioral interventions for children which are simple
and practical including positive reinforcement with rewards,
diaries, stickers on calendars, goal setting, contracts, and
linking medication intake with established daily routines,
among others [49, 57–63]. The most common behavioral
interventionisthetokenreinforcement system, where adher-
ence to medication is rewarded by tokens or another form
of reward [64–66]. It is important to inquire about medica-
tion/formulationpreferencesbeforeprescribing prophylactic
antibiotics(pill,capsule,orelixirform,and preferredﬂavor).
Changing a medication to a more palatable form was shown
to be eﬀective in increasing adherence rates in children [67,
68]. A common complaint by parents/children with liquid
nitrofurantoin is its poor taste. Perhaps the poor palatability
may partly explain the distinctly low adherence rate of only
2% observed in children on nitrofurantoin prophylaxis for
VUR [22]. Finally, the involvement of family members and
schools can be valuable in improving adherence in children
[35, 47].
While the underlying reasons for nonadherence in ado-
lescents are complex and not fully understood, issues involv-
ing self-esteem, body image, coping mechanisms, and self
motivation are contributing factors [38]. As children age
and enter adolescence they become more autonomous and
assume a greater responsibility for their own treatment
[69]. In general, increased age is associated with lower
adherence across many chronic pediatric illnesses includ-
ing asthma, anxiety disorders, diabetes, and HIV [69–72].
Similar ﬁndings were noted by the Hensle et al. [21]a n d
Copp et al. [22] groups with pediatric patients on CAP for
VUR. This underscores the need for educational strategies
targeted at the adolescent, as well as continuous parental
oversight particularly as the child/adolescentis granted more
autonomy.
5.Conclusion
The goal of prophylactic antibiotics is to maintain urine
sterility and prevent ascending urinary tract infections
in children with vesicoureteral reﬂux until the condition
resolves spontaneously or is surgically corrected. Nonadher-
ence to prophylactic antibiotics among children is highly
prevalent and may be associated with medication fail-
ure, unnecessary changes in treatment protocols, increased
healthcare costs, and increased antibiotic resistance patterns.
We must strive to identify risk factors for nonadherence, and
implement behavioral/educational algorithms to improve
adherence. Finally, in light of emerging data supporting
the contention that prophylactic antibiotics may not be
protective against UTIs, controlled studies that monitor and
adequately account for adherence rates are needed. Until
such studies are available, we cannot reliably determine
whether antibiotic prophylaxis is eﬀective in preventing
urinary tract infection in children with vesicoureteral reﬂux.
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